Latest Clinical Services News

Doctor Care Anywhere has reported a profitable first half of 2025, driven by strong margin improvements and operational efficiencies. The telehealth provider’s strategic expansion and app enhancements signal promising growth ahead.

Apiam Animal Health posted modest FY25 growth amid challenges in clinical services, launching a Strategic Reset Program and attracting an acquisition proposal from Adamantem Capital.

Epsilon Healthcare has emerged from Administration, securing expanded medicinal cannabis manufacturing permits and launching a new pharmacy brand as part of a strategic turnaround and growth plan.

Vitura Health’s joint venture Flora Holdings has acquired Heyday Medical Clinic, a leading medicinal cannabis provider, enhancing its national clinical network and patient access across Australia.

Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Little Green Pharma has finalized the acquisition of Health House, a key medicinal cannabis distributor, for a fraction of its previous valuation, marking a strategic move to deepen vertical integration.

Epsilon Healthcare's December 2023 quarterly report reveals significant boardroom conflict and governance breaches, yet operational segments show promising growth.

Emyria Limited reports strong progress in its MDMA and psilocybin-assisted therapy programs alongside a successful $2.525 million capital raise, positioning the company for expanded mental health treatment services.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.